36.63
+0.84(+2.35%)
Currency In USD
| Previous Close | 35.79 |
| Open | 35.81 |
| Day High | 37 |
| Day Low | 35.42 |
| 52-Week High | 43.73 |
| 52-Week Low | 4.55 |
| Volume | 1.93M |
| Average Volume | 2.01M |
| Market Cap | 5.95B |
| PE | -16.96 |
| EPS | -2.16 |
| Moving Average 50 Days | 36.5 |
| Moving Average 200 Days | 27.51 |
| Change | 0.84 |
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
GlobeNewswire Inc.
Feb 28, 2026 2:45 PM GMT
Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalizationStrong ev
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
GlobeNewswire Inc.
Feb 10, 2026 1:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming post
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
GlobeNewswire Inc.
Jan 26, 2026 1:00 PM GMT
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.